1. Home
  2. TEVA vs INVH Comparison

TEVA vs INVH Comparison

Compare TEVA & INVH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TEVA
  • INVH
  • Stock Information
  • Founded
  • TEVA 1901
  • INVH 2012
  • Country
  • TEVA Israel
  • INVH United States
  • Employees
  • TEVA N/A
  • INVH N/A
  • Industry
  • TEVA Biotechnology: Pharmaceutical Preparations
  • INVH Real Estate
  • Sector
  • TEVA Health Care
  • INVH Finance
  • Exchange
  • TEVA Nasdaq
  • INVH Nasdaq
  • Market Cap
  • TEVA 20.1B
  • INVH 21.1B
  • IPO Year
  • TEVA N/A
  • INVH 2017
  • Fundamental
  • Price
  • TEVA $16.65
  • INVH $32.89
  • Analyst Decision
  • TEVA Strong Buy
  • INVH Buy
  • Analyst Count
  • TEVA 8
  • INVH 17
  • Target Price
  • TEVA $24.50
  • INVH $38.26
  • AVG Volume (30 Days)
  • TEVA 10.6M
  • INVH 3.4M
  • Earning Date
  • TEVA 07-30-2025
  • INVH 07-23-2025
  • Dividend Yield
  • TEVA N/A
  • INVH 3.52%
  • EPS Growth
  • TEVA N/A
  • INVH N/A
  • EPS
  • TEVA N/A
  • INVH 0.78
  • Revenue
  • TEVA $16,616,000,000.00
  • INVH $2,618,857,000.00
  • Revenue This Year
  • TEVA $5.69
  • INVH $5.35
  • Revenue Next Year
  • TEVA N/A
  • INVH $3.74
  • P/E Ratio
  • TEVA N/A
  • INVH $42.31
  • Revenue Growth
  • TEVA 3.82
  • INVH 6.04
  • 52 Week Low
  • TEVA $12.47
  • INVH $29.37
  • 52 Week High
  • TEVA $22.80
  • INVH $37.80
  • Technical
  • Relative Strength Index (RSI)
  • TEVA 45.87
  • INVH 40.54
  • Support Level
  • TEVA $16.42
  • INVH $32.18
  • Resistance Level
  • TEVA $16.95
  • INVH $33.07
  • Average True Range (ATR)
  • TEVA 0.46
  • INVH 0.56
  • MACD
  • TEVA -0.11
  • INVH -0.08
  • Stochastic Oscillator
  • TEVA 16.79
  • INVH 30.36

About TEVA Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

About INVH Invitation Homes Inc.

Invitation Homes owns a portfolio of over 85,000 single-family rental homes. The company focuses on owning homes in the starter and move-up segments of the housing market with an average sale price around $350,000 and generally less than 1,800 square feet. The portfolio is spread across 16 target markets that feature high employment and household formation growth with almost 70% of the portfolio in the Western U.S. and Florida; 15 of the 16 markets featuring average rents lower than homeownership costs.

Share on Social Networks: